NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $247.20 +9.31 (+3.91%) Closing price 09/15/2026 03:59 PM EasternExtended Trading$248.00 +0.80 (+0.32%) As of 07:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Quest Diagnostics Stock (NYSE:DGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quest Diagnostics alerts:Sign Up Key Stats Today's Range$237.21▼$248.6550-Day Range$201.64▼$247.2052-Week Range$171.18▼$248.65Volume1.37 million shsAverage Volume879,921 shsMarket Capitalization$27.28 billionP/E Ratio26.24Dividend Yield1.39%Price Target$236.31Consensus RatingModerate Buy Company Overview Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing used to help diagnose, monitor and manage diseases and other health conditions, serving physicians, hospitals, health plans, employers, government agencies and individual consumers. Its services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments. Quest also provides laboratory management and diagnostic support services for hospitals and other healthcare organizations, as well as consumer-ordered testing through its retail and digital channels. Quest Diagnostics traces its roots to laboratories established by Corning Incorporated and became an independent public company in 1996. The company is headquartered in Secaucus, New Jersey, and primarily serves customers throughout the United States through a network of laboratories, patient service centers and other healthcare partnerships. Quest is led by President and Chief Executive Officer Jim Davis.AI Generated. May Contain Errors. Read More Quest Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreDGX MarketRank™: Quest Diagnostics scored higher than 79% of companies evaluated by MarketBeat, and ranked 135th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingQuest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 1 strong buy rating, 5 buy ratings, 7 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Quest Diagnostics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageQuest Diagnostics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quest Diagnostics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.35% Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 7.35% in the coming year, from $11.15 to $11.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 26.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 26.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.86.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.17. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Quest Diagnostics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.15% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 3.86, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently increased by 3.74%, indicating that investor sentiment is decreasing. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.45%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 36.52%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 28.74% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. News and Social Media2.4 / 5News Sentiment0.85 News SentimentQuest Diagnostics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Quest Diagnostics this week, compared to 7 articles on an average week.Search InterestOnly 8 people have searched for DGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,316,493.00 in company stock.Percentage Held by Insiders0.88% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DGX Stock News HeadlinesNine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics17 minutes ago | prnewswire.comQuest Diagnostics (NYSE:DGX) Hits New 52-Week High - Here's Why3 hours ago | americanbankingnews.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.September 16 at 1:00 AM | American Alternative (Ad)Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference TranscriptSeptember 15 at 3:00 PM | seekingalpha.comQuest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 15 at 2:28 AM | americanbankingnews.comQuest Diagnostics Incorporated (DGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14 at 4:40 PM | seekingalpha.comZacks Research Expects Lower Earnings for Quest DiagnosticsSeptember 13 at 1:29 AM | americanbankingnews.comQuest Diagnostics (NYSE:DGX) SVP Michael Prevoznik Sells 22,677 Shares of StockSeptember 1, 2026 | insidertrades.comSee More Headlines DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $173.47 at the beginning of 2026. Since then, DGX shares have increased by 42.5% and is now trading at $247.1970. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) posted its earnings results on Thursday, July, 23rd. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics's quarterly revenue was up 10.2% on a year-over-year basis. Read the conference call transcript. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics' board initiated a stock buyback plan on Tuesday, February 10th 2026, which permits the company to repurchase $1,000,000,000 in shares, according to EventVestor. This means that the company could purchase up to 4.7% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its shares are undervalued. Does Quest Diagnostics have any subsidiaries? The following companies are subsidiaries of Quest Diagnostics: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and more. When did Quest Diagnostics IPO? Quest Diagnostics (DGX) raised $12 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 2,300,000 shares at $4.00-$6.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO. Who are Quest Diagnostics' major shareholders? Top institutional shareholders of Quest Diagnostics include BlackRock Inc. (8.40%), Bank of America Corp DE (1.75%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.85%) and Legal & General Group Plc (0.65%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Gary M Pfeiffer, Vicky B Gregg, Patrick Plewman, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Record date for 7/22 Dividend7/08/2026Ex-Dividend for 7/22 Dividend7/08/2026Dividend Payable7/22/2026Last Earnings7/23/2026Today9/16/2026Record date for 10/21 Dividend10/06/2026Ex-Dividend for 10/21 Dividend10/06/2026Next Earnings (Estimated)10/20/2026Dividend Payable10/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DGX's financial health is in the Green zone, according to TradeSmith. DGX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNYSE:DGX CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees57,000Year Founded1967Price Target and Rating Average Price Target for Quest Diagnostics$236.31 High Price Target$260.00 Low Price Target$200.00 Potential Upside/Downside-4.4%Consensus RatingModerate Buy Rating Score (0-4)2.54 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$9.42 Trailing P/E Ratio26.24 Forward P/E Ratio22.17 P/E Growth2.17Net Income$992 million Net Margins9.18% Pretax Margin12.15% Return on Equity16.01% Return on Assets7.27% Debt Debt-to-Equity Ratio0.72 Current Ratio1.59 Quick Ratio1.46 Sales & Book Value Annual Sales$11.04 billion Price / Sales2.47 Cash Flow$15.77 per share Price / Cash Flow15.68 Book Value$64.78 per share Price / Book3.82Miscellaneous Outstanding Shares110,370,000Free Float109,402,000Market Cap$27.28 billion OptionableOptionable Beta0.55 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:DGX) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredPass by August 7… or wait until 2027?Most investors hear "privacy coin" and picture one thing. Monero. Zcash. Tokens engineered to make transaction...Crypto 101 Media | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredThis Gold Explorer Is Approaching Its Biggest Milestone YetA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredNNVC on Alert: FDA Validation and Outperform Rating!NanoViricides (NYSE: NNVC) just landed FDA Rare Pediatric Disease Designation for NV-387 in Measles, adding to...Equiscreen | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
